Abciximab

Active ingredient description

Abciximab is the Fab fragment of the chimeric monoclonal antibody 7E3. It is directed against the glycoprotein (GP) IIb/IIIa (αIIbβ3) receptor located on the surface of human platelets. Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Abciximab
B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AC Platelet aggregation inhibitors excl. heparin
Discover more medicines within B01AC13

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Summary of Product Characteristics (SPC)
UK

Medicines

Abciximab is the active ingredient of these drugs:

Drug
Countries

Turkey

Brazil

Chemical formula: C₂₂H₂₇ClN₄O₃S
Molecular mass: 462.149 g/mol

External identifiers

CAS Substance: 143653-53-6
DrugBank Drug: DB00054
KEGG Drug: D02778
RxNorm Ingredient: 83929
SNOMED-CT Concept: 386951001
Abciximab (substance)
UNII Identifier: X85G7936GV
ABCIXIMAB